首页> Nature communications> MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance.

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance.

导出 OA

翻译打印收藏纠错

第一作者： Matthew J,Sale

第一单位： Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. matthew.sale@babraham.ac.uk.

作者： Matthew J,Sale ^[1] ; Kathryn,Balmanno ^[2] ; Jayeta,Saxena ^[2] ; Eiko,Ozono ^[2] ; Katarzyna,Wojdyla ^[3] ; Rebecca E,McIntyre ^[4] ; Rebecca,Gilley ^[2] ; Anna,Woroniuk ^[2] ; Karen D,Howarth ^[5] ; Gareth,Hughes ^[6] ; Jonathan R,Dry ^[7] ; Mark J,Arends ^[8] ; Pilar,Caro ^[2] ; David,Oxley ^[3] ; Susan,Ashton ^[9] ; David J,Adams ^[4] ; Julio,Saez-Rodriguez ^[10] ; Paul D,Smith ^[6] ; Simon J,Cook ^[11]

作者单位： Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. matthew.sale@babraham.ac.uk. ^[1] Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. ^[2] Proteomics Facility, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. ^[3] Experimental Cancer Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, UK. ^[4] Hutchison-MRC Research Centre, Department of Pathology, University of Cambridge, Hills Road, Cambridge, CB2 0XZ, UK. ^[5] Oncology Bioscience, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, CRUK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK. ^[6] Oncology Bioscience, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA. ^[7] Division of Pathology, Centre for Comparative Pathology, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, UK. ^[8] Oncology Bioscience, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, UK. ^[9] European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK. ^[10] Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. simon.cook@babraham.ac.uk. ^[11]